ondansetron has been researched along with Precursor Cell Lymphoblastic Leukemia-Lymphoma in 16 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Precursor Cell Lymphoblastic Leukemia-Lymphoma: A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 9.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| " The study was open, dose ranging, and noncomparative, and designed to evaluate safety and efficacy of ondansetron in preventing nausea and vomiting caused by cyclophosphamide intravenous (IV) 1,000 mg/m2 day 1, and cytarabine IV subcutaneously (SC) 75 mg/m2 on days 2 to 5." | 9.06 | Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia. ( Carden, PA; Ekert, H; Mitchell, SL; Tiedemann, K; Waters, KD, 1990) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 7.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| "To measure the severity of nausea and vomiting in pediatric patients receiving intravenous or intrathecal chemotherapy for acute lymphoblastic leukemia and to evaluate the effectiveness of 2 intravenous doses of ondansetron for this condition." | 7.69 | Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. ( Chavez, CM; Duncan, MH; Holdsworth, MT; Leasure, MM; Raisch, DW, 1995) |
| "One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min." | 6.68 | [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. ( Fan, Y; Guo, N; Huang, X, 1995) |
| "Ondansetron is a cost effective and safe antiemetic in children receiving chemotherapy and total body irradiation, minimises weight loss on treatment and enables outpatient chemotherapy in some cases." | 5.28 | Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. ( Abbott, GD; Robinson, BA; Sullivan, MJ, 1992) |
| "During the first 12 hr following the procedures, patients experienced significantly less vomiting/retching and less disruption of activity while receiving ondansetron, and recorded significantly lower pain scores while receiving fentanyl." | 5.13 | Pediatric oncology sedation trial (POST): A double-blind randomized study. ( Barr, RD; Buckley, N; Korz, L; Lappan, J; Nagel, K; Willan, AR, 2008) |
| "5-HT3 receptor antagonists, including granisetron and ondansetron, are widely used in the prophylactic treatment of chemotherapy-induced nausea and vomiting." | 5.11 | The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia. ( Buyukavci, M; Ceviz, N; Olgun, H, 2005) |
| "The serotonin (5HT3) antagonist ondansetron was compared in a randomised study with metoclopramide and dexamethasone for the prevention of chemotherapy induced emesis." | 5.08 | Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis. ( Dick, GS; Meller, ST; Pinkerton, CR, 1995) |
| " The study was open, dose ranging, and noncomparative, and designed to evaluate safety and efficacy of ondansetron in preventing nausea and vomiting caused by cyclophosphamide intravenous (IV) 1,000 mg/m2 day 1, and cytarabine IV subcutaneously (SC) 75 mg/m2 on days 2 to 5." | 5.06 | Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia. ( Carden, PA; Ekert, H; Mitchell, SL; Tiedemann, K; Waters, KD, 1990) |
| " Initially, for his leukemia, he was treated with chemotherapy, which resulted in severe nausea and vomiting for which he was given ondansetron." | 3.74 | The successful use of ondansetron in a boy with both leukemia and Tourette syndrome. ( Gulisano, M; Marino, S; Rizzo, R; Robertson, MM, 2008) |
| "The purpose of this study was to document the emetogenic potential of intrathecal chemotherapy (IC) in children and to evaluate the efficacy of ondansetron in reducing nausea and vomiting with this chemotherapy treatment." | 3.70 | Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron. ( Chavez, CM; Holdsworth, MT; Raisch, DW; Winter, SS, 1998) |
| "To measure the severity of nausea and vomiting in pediatric patients receiving intravenous or intrathecal chemotherapy for acute lymphoblastic leukemia and to evaluate the effectiveness of 2 intravenous doses of ondansetron for this condition." | 3.69 | Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia. ( Chavez, CM; Duncan, MH; Holdsworth, MT; Leasure, MM; Raisch, DW, 1995) |
| "One hundred sixteen cases of leukemia patients received supra-high single dose TBI for bone marrow transplantation (BMT) with total a radiation dosage of 700-770 Gy at about 5cGy/min." | 2.68 | [Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)]. ( Fan, Y; Guo, N; Huang, X, 1995) |
| "Ondansetron is a cost effective and safe antiemetic in children receiving chemotherapy and total body irradiation, minimises weight loss on treatment and enables outpatient chemotherapy in some cases." | 1.28 | Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children. ( Abbott, GD; Robinson, BA; Sullivan, MJ, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (43.75) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 5 (31.25) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernhardt, MB | 1 |
| Prada, J | 3 |
| Long, H | 1 |
| Nagel, K | 1 |
| Willan, AR | 1 |
| Lappan, J | 1 |
| Korz, L | 1 |
| Buckley, N | 1 |
| Barr, RD | 1 |
| Shalapour, S | 2 |
| Pfau, M | 2 |
| Henze, G | 2 |
| Seeger, K | 2 |
| Siddique, R | 1 |
| Hafiz, MG | 1 |
| Rokeya, B | 1 |
| Jamal, CY | 1 |
| Islam, A | 1 |
| Buyukavci, M | 1 |
| Olgun, H | 1 |
| Ceviz, N | 1 |
| Aapro, M | 1 |
| Rabaeus, M | 1 |
| Rizzo, R | 1 |
| Marino, S | 1 |
| Gulisano, M | 1 |
| Robertson, MM | 1 |
| Dick, GS | 1 |
| Meller, ST | 1 |
| Pinkerton, CR | 1 |
| Huang, X | 1 |
| Guo, N | 1 |
| Fan, Y | 1 |
| Holdsworth, MT | 2 |
| Raisch, DW | 2 |
| Duncan, MH | 1 |
| Chavez, CM | 2 |
| Leasure, MM | 1 |
| Dixon, CM | 1 |
| Colthup, PV | 1 |
| Serabjit-Singh, CJ | 1 |
| Kerr, BM | 1 |
| Boehlert, CC | 1 |
| Park, GR | 1 |
| Tarbit, MH | 1 |
| Winter, SS | 1 |
| Sullivan, MJ | 1 |
| Abbott, GD | 1 |
| Robinson, BA | 1 |
| Carden, PA | 1 |
| Mitchell, SL | 1 |
| Waters, KD | 1 |
| Tiedemann, K | 1 |
| Ekert, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Ondansetron Premedication Trial in Juvenile Idiopathic Arthritis[NCT04169828] | 176 participants (Anticipated) | Interventional | 2019-08-02 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 trials available for ondansetron and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Pediatric oncology sedation trial (POST): A double-blind randomized study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Biopsy, Needle; Bone Marrow Examination; Child; Chil | 2008 |
Ondansetron versus granisetron in the prevention of chemotherapy induced nausea and vomiting in children with acute lymphoblastic leukemia.
Topics: Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Double-Blind Method; Female; Granisetro | 2011 |
The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Adolescent; Antiemetics; Antimetabolites, Antineoplastic; Child; Child, Preschool; Electrocardiograp | 2005 |
Randomised comparison of ondansetron and metoclopramide plus dexamethasone for chemotherapy induced emesis.
Topics: Administration, Oral; Adolescent; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child | 1995 |
[Ondansetron in the prophylaxis of acute emesis induced by supra-high single dose total body irradiation (TBI)].
Topics: Adult; Female; Humans; Leukemia, Myeloid, Acute; Male; Nausea; Ondansetron; Precursor Cell Lymphobla | 1995 |
Prevention of cyclophosphamide/cytarabine-induced emesis with ondansetron in children with leukemia.
Topics: Administration, Oral; Adolescent; Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols | 1990 |
10 other studies available for ondansetron and Precursor Cell Lymphoblastic Leukemia-Lymphoma
| Article | Year |
|---|---|
Nausea and vomiting: Therapeutic orphans of pediatric oncology.
Topics: Antiemetics; Child; Child, Preschool; Granisetron; Humans; Methotrexate; Nausea; Ondansetron; Precur | 2017 |
Significant decreases of interleukin-1α gene expression after application of the serotonin receptor antagonist ondansetron are found to correlate with antiproliferative properties in the acute lymphoblastic leukemia cell line REH.
Topics: Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, | 2015 |
Antiproliferative effect of the serotonin receptor antagonist ondansetron in the acute lymphoblastic leukemia cell line REH.
Topics: Cell Proliferation; Humans; Ondansetron; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Serotonin A | 2011 |
The serotonin receptor-antagonist ondansetron induces significant increases in the expression of interferon-gamma which correlate with antiproliferative properties in the acute lymphoblastic leukaemia cell line REH.
Topics: Cell Line, Tumor; Cell Proliferation; Humans; Interferon-gamma; Ondansetron; Precursor Cell Lymphobl | 2012 |
Re: The effects of ondansetron and granisetron on electrocardiography in children receiving chemotherapy for acute leukemia.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Electrocardiography; Granisetron | 2005 |
The successful use of ondansetron in a boy with both leukemia and Tourette syndrome.
Topics: Anti-Dyskinesia Agents; Antiemetics; Antineoplastic Agents; Biperiden; Brain; Child; Dose-Response R | 2008 |
Assessment of chemotherapy-induced emesis and evaluation of a reduced-dose intravenous ondansetron regimen in pediatric outpatients with leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Eto | 1995 |
Multiple forms of cytochrome P450 are involved in the metabolism of ondansetron in humans.
Topics: Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Female; Genetic Engineering; H | 1995 |
Assessment of the emetogenic potential of intrathecal chemotherapy and response to prophylactic treatment with ondansetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Fe | 1998 |
Ondansetron antiemetic therapy for chemotherapy and radiotherapy induced vomiting in children.
Topics: Child; Child, Preschool; Humans; Lymphoma, T-Cell; Nausea; Ondansetron; Precursor Cell Lymphoblastic | 1992 |